Johnson & Johnson Reports 42% Response Rate for Advanced Head and Neck Cancer Therapy

MT Newswires Live06-01 17:10

Johnson & Johnson (JNJ) said Sunday that data from a phase 1b/2 study showed its experimental therapy, subcutaneous amivantamab and hyaluronidase-lpuj, achieved a 42% confirmed overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with immunotherapy and platinum-based chemotherapy.

The primary endpoint was overall response rate, with the more than one-third of responders achieving complete responses, the company said.

Median duration of response had not been reached at a median follow-up of 11.8 months, the company said.

The company in the 102-patient study cohort, median progression-free survival was 6.8 months and median overall survival was 12.5 months.

A supplemental Biologics License Application seeking approval for subcutaneous amivantamab in head and neck cancer has been submitted to the U.S. Food and Drug Administration (FDA), it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment